Rethinking the Standard: Does Less Mean More for Frail Elderly Patients with Head and Neck Cancer?
The ELAN-RT trial demonstrates that hypofractionated split-course radiotherapy is non-inferior to standard fractionation for 6-month locoregional response in frail older patients, providing a less toxic alternative, though standard therapy remains superior for overall survival in those who can tolerate it.